Global Lung Cancer Vaccine Market Sales Revenue Clinical Trials Pipeline Report2015

Lung cancer incidences are rapidly increasing and various therapeutics have been introduced in global market to provide better care to patients. Surgery and radiation therapy are not preferred for lung cancer treatment due to which they have small global market size. Chemotherapeutics and targeted therapeutics for lung cancer treatment are major market contender in global market with wide acceptance levels among oncologists and patients. Chemotherapeutics have life threatening side effects while targeted therapeutics available in markets are quite effective therapeutics but they are unable to reduce the present lung cancer mortality rates. These drawbacks are not expected to be associated with lung cancer vaccines which will help in generating significant revenues and increased penetration across the globe.

Download Report:

https://www.kuickresearch.com/report-Global-Lung-Cancer-Vaccine-Market-&-Pipeline-Insight-2015.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Global Lung Cancer Vaccine Market & Pipeline Insight 2015" Table of Contents

1. Introduction to Cancer Vaccines

2. Cancer Vaccines: Mechanism & Innovations
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Introduction Global Lung Cancer Vaccine

4. Mechanism of Lung Cancer Vaccines

5. Global Lung Cancer Vaccine Market Outlook
5.1 Current Market Scenario
5.2 Global Lung Cancer Vaccines Pipeline Overview

6. Global Lung Cancer Market Dynamics
6.1 Favorable Market Parameters
6.2 Market & Commercialization Challenges

7. Global Lung Cancer Vaccine Market Future Prospects

8. Global Lung Cancer Vaccine Pipeline by Company & Phase
8.1 Preclinical
8.2 Clinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III

9. Marketed Lung Cancer Vaccine Clinical Insight
9.1 BV NSCLC 001
9.2 Mycidac-C™
9.3 Vaxira®

10. Suspended & Discontinued Lung Cancer Vaccines Pipeline by Company & Phase
10.1 No Development Reported
10.2 Discontinued

11. Competitive Landscape
11.1 Boehringer Ingelheim
11.2 CureVac
11.3 Eli Lily
11.4 Galaxo
11.5 ImClone Systems
11.6 Merck
11.7 Ono Pharmaceutical
11.8 Oncothyreon Incorporation

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Functions of Lungs
Figure 3-2: Factors Responsible for Increasing Lung Cancer Incidences
Figure 4-1: Type of Lung Cancer
Figure 4-2: Types of Lung Cancer Treatment
Figure 4-3: Mechanism of MAGE-3 Lung Cancer Vaccine
Figure 4-4: Mechanism of p53 Lung Cancer Vaccine
Figure 4-5: Mechanism of NY-ESO-1 Lung Cancer Vaccine
Figure 5-1: Global Lung Cancer Vaccines Pipeline (%), 2015
Figure 5-2: Global Lung Cancer Vaccines Pipeline (Number), 2015
Figure 5-3: No Development Reported in Lung Cancer Vaccines Pipeline (%), 2015
Figure 5-4: No Development Reported in Lung Cancer Vaccines Pipeline (Number), 2015
Figure 5-5: Discontinued Lung Cancer Vaccines Pipeline (%), 2015
Figure 5-6: Discontinued Lung Cancer Vaccines Pipeline (Number), 2015
Figure 6-1: Drivers for Lung Cancer Vaccines
Figure 6-2: Market & Commercialization Challenges

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.